Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis. Issue 11 (22nd November 2022)

• Record Type: Journal Article
• Authors: Hu, Kelly A.; Shen, Jeanne; Rieger, Kerri; Wei, Mike T.; Gubatan, John
• Is Part Of: ACG Case Reports Journal. Volume 9:Issue 11(2022)
• Page Start: e00881
• Publication Date: 2022-11-22
• DOI: 10.14309/crj.0000000000000881
• Languages: English
• ISSNs: 2326-3253

Abstract

ABSTRACT: Ustekinumab, an inhibitor of the interleukin-12/23 pathway, received Food and Drug Administration (FDA) approval in 2019 for induction and maintenance therapy in patients with moderate-to-severe ulcerative colitis (UC). Data regarding the efficacy of ustekinumab in the treatment of extraintestinal manifestations of UC are unclear. Sweet syndrome, an acute febrile neutrophilic dermatosis, is a cutaneous manifestation of inflammatory bowel disease that parallels disease activity. In this study, we present the first case of subcutaneous Sweet syndrome with sterile osteomyelitis in a patient with UC successfully treated with ustekinumab.